glp-1 pharmacokinetics Evaluation of the of receptor agonist delivered through the BioJet™ oral biotherapeutic delivery platform in a porcine model Table 3 from Glucagon-Like Peptide-1

The main difference is how and how often theyre taken.Similarities: Both are FDA-approved Wegovy formulations Both use semaglutide as the active ingredient Both follow a gradual dose-increase schedule determined by a provider Side effects are generally similar and can be managed with provider support Differences: Wegovy pen: Taken as a once-weekly injection Wegovy pill: Taken orally once per day Your Shed provider will help determine which option may be appropriate based on your health history, preferences, and treatment goals

Mounjaro generally outperforms Ozempic in terms of A1C reduction and weight loss

This experience is most commonly reported by people using GLP-1 receptor agonists like semaglutide and tirzepatide, medications originally developed for type 2 diabetes and now widely used for medical weight management

The trials lasted for 72 days

Abbreviations CVD: Cardiovascular disease T2D: Type 2 diabetes CV: Cardiovascular HF: Heart failure GLP-1RA: Glucagon-like peptide 1 receptor agonist SGLT-2: Sodium-glucose cotransporter 2 MACE: Major cardiovascular events MI: Myocardial infarction ADA: American Diabetes Association HFrEF: Heart failure with reduced ejection fraction HFpEF: Heart failure with preserved ejection fraction FDA: Food and Drug Administration NHANES: National Health and Nutrition Examination Survey CKD: Chronic kidney disease References Grundy SM, Benjamin IJ, Burke GL, et al

doi: 10.2337/diabetes.52.7.1786 [DOI] [PubMed] [Google Scholar] 121